ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma
S. Wenzel, D. Chantry, C. Eberhardt, R. Hopkins, M. Saunders, L. Anderson, R. Aitchinson, S. Bell, K. Izuhara, J. Ono, L. Burgess (Pittsburgh, Boulder, United States Of America; Saga, Tokyo, Japan)
Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Wenzel, D. Chantry, C. Eberhardt, R. Hopkins, M. Saunders, L. Anderson, R. Aitchinson, S. Bell, K. Izuhara, J. Ono, L. Burgess (Pittsburgh, Boulder, United States Of America; Saga, Tokyo, Japan). ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma. Eur Respir J 2014; 44: Suppl. 58, 4836
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: